English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

[6] Shepherd J, Cobbe SM, Ford I et al, for The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7. [7] The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36-69. [8] Study Group, European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur Heart J 1987; 8: 77-88. [9] Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel II). JAMA 1993; 269: 3015-23. [10] Scandinavian Simvastatin Survival Study Group. (Writing committee: Pedersen TR, Kjekshus J, Berg K et al). Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1274-5. [11] Davidson MH, Stein EA, Dujovne CA, Hunninghake DB et al. The efficacy and six-week tolerability of simvastatin 80 and 160mg/day. Am J Cardiol 1997; 79: 38^t2. [12] Nawrocki JW, Weiss SR, Davidson MH et at. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vase Biol 1995; 15: 678-82.

Digoxin in heart failure: results of the recent digoxin investigation group trial in the context of other treatments for heart failure